Casi pharmaceuticals appoints david cory as chief executive officer to lead u.s. company focused on clinical development of cid-103, a potential best in class anti-cd38 program

-- david cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1b+ raised and multiple company exits by acquisition -- cid-103 is a potential best in class, anti-cd38 monoclonal antibody, currently dosing in a multi-center phase 1/2 study in adults with chronic immune thrombocytopenia (itp); ind submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (amr) beijing, cn / access newswire / july 21, 2025 / casi pharmaceuticals, inc. (nasdaq:casi), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the appointment of david cory as chief executive officer and a member of the board of directors. wei-wu he, ph.d.
CASI Ratings Summary
CASI Quant Ranking